CLR/RAMP1, or CGRP receptor, antagonists have been developed for thetreatment of migraine headache and osteoarthritis pain; whereas CLR/RAMP2, orADM receptor, antagonists are being developed for the treatment of tumorgrowth/metastasis. This evidence concerns the gene DCLK3 and Headache.